MedTrace Logo

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

NCT06786338 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-01-22

No results posted yet for this study

Summary

This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.

Conditions

  • IgA Nephropathy (IgAN)
  • C3 Glomerulopathy
  • IC-MPGN

Interventions

DRUG

SGB-9768

SGB-9768 for subcutaneous (SC) injection

Sponsors & Collaborators

  • Suzhou Sanegene Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-07-01
Completion
2026-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786338 on ClinicalTrials.gov